Eikon Therapeutics is a biopharmaceutical company. It engages in the development of medicines for unmet medical needs. The company was founded in 2019 and is headquartered in Millbrae, CA.
相关临床试验
9
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
11.1%
已完成
4
44.4%
招募中
4
44.4%
暂无批准数据
- Generate Biomedicines, backed by Flagship Pioneering, is seeking to raise up to $425 million in its U.S. IPO with a target valuation of $2.17 billion. - The AI-powered drug discovery company uses artificial intelligence to replace traditional trial-and-error methods and create novel protein-based therapeutics focused on immunology and oncology. - The company's lead candidate GB-0895 for severe asthma treatment is currently in late-stage trials, with full enrollment expected by the first half of 2028. - The IPO comes amid a resurgent biotech market in 2026, though investors remain cautious about AI drug discovery platforms as no fully AI-discovered drug has achieved FDA approval yet.
- Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in separate IPOs on Thursday, with both companies beginning Nasdaq trading on Friday. - The offerings represent the third and fourth biotech IPOs this week, marking the busiest seven-day stretch for new biotech stock offerings in about a year. - Agomab's lead candidate ontunisertib targets fibrostenosing Crohn's disease and is currently in Phase 2 trials, while SpyGlass's bimatoprost drug-device system for glaucoma entered Phase 3 studies in July 2025. - The successful IPOs reflect growing investor confidence in biotech, with several 2025 debuts seeing share values more than double since their offerings.
- Eikon Therapeutics, led by former Merck executive Roger Perlmutter, filed for a $100 million IPO to fund development of experimental cancer treatments. - The company is advancing EIK1001, a TLR 7/8 dual-agonist, in global Phase 2/3 trials for advanced melanoma with 740 patients and stage 4 NSCLC with 750 patients. - Eikon's pipeline includes selective PARP1 inhibitors EIK1003 and EIK1004 in Phase 1/2 trials for ovarian and breast cancers. - The biotech has secured over $1 billion in private funding since its 2019 founding and plans to list on Nasdaq under symbol EIKN.
- Eikon Therapeutics will present new Phase 2 data on EIK1001, a novel TLR7/8 co-agonist, in combination with pembrolizumab and chemotherapy for first-line treatment of stage 4 non-small cell lung cancer at ESMO 2025. - The TeLuRide-005 study results have been reviewed in a successful end-of-Phase-2 meeting with the FDA, supporting advancement into a registration-enabling Phase 2/3 trial. - EIK1001 is designed to stimulate broad immune activation through TLR7/8 co-activation to enhance T-cell recognition and tumor killing in advanced NSCLC patients. - The company is also advancing EIK1001 in a seamless Phase 2/3 trial for advanced melanoma, demonstrating momentum across its oncology pipeline.
- Repertoire Immune Medicines has appointed Robert Andtbacka, MD, as Chief Medical Officer to strengthen leadership as the company prepares for its first clinical trial. - The company's lead candidate RPTR-1-201, a TCR bispecific targeting novel peptides on solid tumors, is progressing through IND-enabling studies following positive regulatory interactions. - RPTR-1-201 represents Repertoire's first clinical-stage asset discovered using their proprietary DECODE platform, with plans to initiate Phase 1/2 trials across multiple cancer indications. - Dr. Andtbacka brings over 20 years of oncology drug development experience from roles at HiFiBiO Therapeutics, Seven and Eight Biopharmaceuticals, and Huntsman Cancer Institute.
- Global pharmaceutical venture capital investments reached $6.5 billion in Q1 2025, showing a slight increase of 0.5% compared to the previous quarter despite a 9% decline in deal volume. - Oncology emerged as the dominant therapeutic area, attracting 76 deals from 217 investors, highlighting continued strong interest in cancer treatment innovations. - The investment landscape showed regional variations and diverse deal stages, with several companies including Eikon Therapeutics and Isomorphic Labs securing significant funding rounds.
- Eikon Therapeutics has successfully raised $350.7 million in Series D funding, bringing their total funding to over $1.1 billion since 2019, with potential for additional investors to join later this year. - The company's lead candidate EIK1001, a TLR7/8 agonist, demonstrated promising Phase I results with 14% response rate in advanced solid tumors and will advance to Phase III trials in advanced melanoma. - Under CEO Roger Perlmutter's leadership, Eikon is expanding its pipeline including PARP1 inhibitors EIK1003 and EIK1004, while preparing for a future IPO at an optimal time.
